Poolbeg Pharma PLC (AIM:POLB)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 31.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.71M |
| Shares Out | 705.10M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 521,854 |
| Average Volume | 1,204,355 |
| Open | 4.640 |
| Previous Close | 4.450 |
| Day's Range | 4.300 - 4.700 |
| 52-Week Range | 2.400 - 5.200 |
| Beta | 1.82 |
| RSI | 51.86 |
| Earnings Date | Apr 2, 2026 |
About Poolbeg Pharma
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated ... [Read more]
Financial Performance
Financial StatementsNews
Poolbeg Pharma Transcript: Study Update
POLB 001 is advancing to a phase 2A trial as a first-in-class oral preventative for cancer immunotherapy-induced CRS, with interim data expected in summer 2023. The program targets a significant unmet need, supported by strong preclinical and phase 1 data, FDA orphan drug status, and a robust financial position.
Poolbeg Pharma Transcript: Investor Update
POLB001 has received FDA orphan drug designation, unlocking regulatory incentives and exclusivity. A phase 2A trial in multiple myeloma patients will start in H2 2025, with interim data in H1 2026. The program targets a $10B+ market, with strong pharma interest and a robust cash runway.
Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market
LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovativ...
Poolbeg Pharma PLC Announces Notification of Major Holdings
LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microso...
Poolbeg Pharma PLC Announces Change of Registered Address
Change of Registered Address LONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and ...
Poolbeg Pharma PLC Announces Result of AGM
Results of Annual General Meeting LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ‘Poolbeg' or the ‘Company'), a biopharmaceutical company focussed on the...
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
LONDON, UK / ACCESSWIRE / May 9, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative...
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
Significant POLB 001 Patent Granted in United States Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON, UK / ACCESSWIRE / May 1, 2024 / P...
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
Significant pipeline advancements Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn Key senior management hires LONDON, UK / ACCESSWIRE / April...
Poolbeg Pharma PLC Announces Appointment of Joint Broker
LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of inn...
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet's Disease Novel therapeutic with Fast Track and Orphan Designation LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma (AIM...
Poolbeg Pharma PLC Announces TR-1: Notification of Major Holdings
LONDON, UK / ACCESSWIRE / April 29, 2024 / TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word for...
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
Notice of Allowance for Significant POLB 001 Patent in United States Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio LONDON, UK / ACCESSWIRE / Mar...
Poolbeg Pharma PLC Announces Director/PDMR Shareholding
Director Share Purchase LONDON, UK / ACCESSWIRE / February 22, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and c...
Poolbeg Pharma PLC Announces Director Share Purchase
LONDON, UK / ACCESSWIRE / February 19, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innov...
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company focussed on the development and commercialisation of innov...
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Former Amryt team's arrival supports inc...
Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion Key highlights - Efficacy demons...
Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV drug candidates with the highest probability of success prioritised LONDON, UK / ACCESSWIRE / December 20, 2023 ...
Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
POLB 001 - targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapies LONDON, UK / ACCESSWIRE / December 11, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Comp...
Poolbeg Pharma PLC Announces Directorate Change
LONDON, UK / ACCESSWIRE / November 30, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innov...
Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
Further enhancement of the patent portfolio LONDON, UK / ACCESSWIRE / November 21, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on t...
Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
POLB 001 - a potential blockbuster immunomodulator LONDON, UK / ACCESSWIRE / November 16, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focuss...
Former Amryt Pharma Leadership Team join Poolbeg
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma Poolbeg team boosted by highly experienced executives with track record of success LONDON, UK / ACCESSWIRE / November 9, 2...
Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
Potential to address cancer treatment related Cytokine Release Syndrome LONDON, UK / ACCESSWIRE / November 3, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical-sta...